aTyr Pharma to Webcast Conference Call Reporting First Quarter 2021 Financial Results

Rhea-AI Summary

aTyr Pharma (Nasdaq: LIFE) will report its first quarter 2021 financial results on May 13, 2021, after market close. The management will host a conference call and webcast at 5:00 pm EDT to discuss the results and provide a corporate update. The company specializes in innovative medicines based on biological pathways, focusing on ATYR1923, a candidate for inflammatory lung diseases. For more details, visit aTyr Pharma's website.

Positive

• Upcoming financial results expected to provide insights into company performance.
• Focus on ATYR1923, a promising therapy for inflammatory lung diseases.

Negative

• None.

Management to host conference call and webcast on May 13th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report first quarter 2021 financial results and provide a corporate update after the market close on Thursday, May 13, 2021. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:
Thursday, May 13th @ 5:00 pm EDT / 2:00 pm PDT
Domestic: 844-358-9116
International: 209-905-5951
Conference ID: 6867948
Webcast: http://investors.atyrpharma.com/events-and-webcasts

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com 

FAQ

When will aTyr Pharma report its financial results?

aTyr Pharma will report its first quarter 2021 financial results on May 13, 2021.

What time is the aTyr Pharma conference call?

The conference call will be held at 5:00 pm EDT / 2:00 pm PDT on May 13, 2021.

What is aTyr Pharma's focus in its research and development?

aTyr Pharma focuses on innovative medicines based on novel biological pathways, particularly ATYR1923 for inflammatory lung diseases.